Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information...
Cheers
Ulf
5.08.2014
No linear association between drug prices and perceived benefit criticises US cancer expert...
Dear all,
pricing of cancer drugs and now also hepatitis C has steered another debate among US payers and physicians about drug prices. See a recent article in business week.
No comments:
Post a Comment